ESMO 2022: Enfortumab Vedotin Plus Pembrolizumab Versus Pembrolizumab Alone for Urothelial Carcinoma

Peter O’Donnell describes the randomized phase 2 study on enfortumab vedotin and pembrolizumab against pembrolizumab alone for the treatment of locally advanced or metastatic urothelial carcinoma.